Physician profile
Hal Skopicki
NPI 1346264553
$30,489.45
in general payments reported to CMS, 2019-2025
24 companies · $308 in 2025
The $308 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $647 · 2021: $12K · 2022: $2,586 · 2023: $295 · 2024: $444 · 2025: $308.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,047.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,047.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $13,071.56 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $11,263.41 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $4,492.60 | 2020-2023 | Lokelma |
| Abbott Laboratories | $1,091.98 | 2019-2025 | Cardiomems, Mitraclip |
| Abiomed | $227.41 | 2024 | Impella |
| Bolton Medical INC | $147.39 | 2021 | |
| Janssen Pharmaceuticals, INC | $48.07 | 2019 | |
| Daiichi Sankyo INC. | $44.71 | 2024 | Injectafer |
| Amgen INC. | $44.53 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $28.13 | 2020-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $18.00 | 2021 | |
| Astellas Pharma US INC | $11.66 | 2019 |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hal Skopicki listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.